Cancer Drugs Market 2022

The global Cancer Drugs market accounted for a market size of USD 6,716.2 Million in 2021 and is projected to reach USD 9,951.2 Million by 2028, at a growth rate of 4.6% during the forecast period.

The global Cancer Drugs market is expected to grow owing to various factors such as the niche penetration of healthcare facilities for cancer diagnostics coupled with the rising healthcare expenditure & government support worldwide. Furthermore, growing prevalence of Cancer Drugs is also estimated to boost the market growth. According to the National Cancer Institute, as of December 2021, around 20-50% cancer patients suffer from pain. Also, according to the Centers for Disease Control and Prevention (CDC), roughly 15.5 million cancer survivors (those who have had a cancer diagnosis) were alive in the United States in 2016, with that figure predicted to rise to over 20 million by 2026. Despite the driving factors, accessibility to facilities and high cost of treatment are expected to hinder the market growth during the forecast period.

Segments Overview:
The global Cancer Drugs market is segmented the drug type and disease indication.

By Drug Type,

  • Opioids/ Narcotics
  • Hydromorphone (Dilaudid)
  • Morphine (Kadian, M-Eslon Others)
  • Codeine
  • Oxycodone
  • Tramadol
  • Fentanyl
  • Others
  • Non-Opioids
  • Acetaminophen
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Nerve Blocks

The opioids/narcotics segment is estimated to account for the largest market share of approximately 75% owing to the growing prevalence of Cancer Drugs and the growing product pipeline. Within this segment, the codeine sub-segment is expected to witness the highest CAGR of 5.5%. This is because codeine is required in less amount as compared to the other opioids. In addition, the non-opioids segment is estimated to account for a market opportunity of around USD 482.7 million during 2022 to 2028. Within this segment, the non-steroidal anti-inflammatory drugs (NSAIDS) segment is estimated to surpass a market size of USD 1,000 million by 2022. This is because of the low cost as well as easy availability of these drugs.

By Disease Indication,

  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Blood Cancer
  • Others

Regional Overview

Based on region, the global Cancer Drugs market is divided into Europe, North America, Asia Pacific, South America, and the Middle East & Africa.

The North America region is expected to hold the largest market share of around 42% in 2021. This amounted to a market size of USD 2,834.8 million. This is owing to the growing incidence rate of cancer and presence of various market players in the region. In the U.S. around 1,194 people below the age of 20 years were suffering from Cancer Drugs in 2021. Total number of people suffering from Cancer Drugs in 2021 in the country was 1,16,182. Also, this number was expected to reach 1,743 people below the age of 20 and 1,59,889 total population suffering from Cancer Drugs by 2028.

Asia Pacific region witnessed the fastest growth rate of 5.7% during the forecast period owing to the easy availability of pain therapeutics, growing geriatric population, and rising awareness of cancer.

Competitive Landscape
Key players operating in the global Cancer Drugs market include Orexo AB, MundiPharma International Ltd., Biodelivery Sciences International Inc., Hisamitsu Pharma Co., Teva Pharma Industries Ltd., CK life Science (WEX Pharma), Daiichi Sankyo Co., Pfizer Inc., Roche Holding AG, and Other Prominent Players. The cumulative market share of 4 major players is near about 35%.

These market players are involved in collaborations, mergers & acquisitions, and new product launches to strengthen their market presence. For instance, in December 2021, Pfizer collaborated with Amazon Web Services, Inc. (AWS) for creating cloud-based solutions for improving the development, manufacturing, and distribution of medicines for clinical trials testing. The company enhanced the company’s position in the market.

Free Sample Report @ https://statisticalinsights.com/sample-request/12-Cancer-Drugs-Market

TABLE OF CONTENTS

Chapter 1. Research Framework
1.1. Objective
1.2. Product Overview
1.2.1. Market Segmentation
1.2.2. Market & Segment Definitions
1.3. Research Methodology
1.3.1. Supply Side (Revenue Analysis)
1.3.2. Demand Side (Spending Analysis)
1.3.3. Data Heads Tracked
1.3.3.1. Quantitative Research
1.3.3.2. Qualitative Research
1.3.4. List of Primary & Secondary Sources
1.3.4.1. Sample Size
1.3.4.2. Sample Distribution
1.3.5. Market Size Estimation
1.3.5.1. Assumption for the Study
1.3.5.2. Data Triangulation

…

Chapter 6. Global Cancer Drugs Market Analysis, By Drug Type
6.1. Key Insights
6.2. Market Size and Forecast, 2017 - 2028 (Revenue - US$ Mn)
6.2.1. Opioids/Narcotics
6.2.1.1. Morphine
6.2.1.2. Fentanyl
6.2.1.3. Others
6.2.2. Non-Opioids
6.2.2.1. Acetaminophen
6.2.2.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
6.2.3. Nerve Blocks

Chapter 7. Global Cancer Drugs Market Analysis, By Disease Indication
7.1. Key Insights
7.2. Market Size and Forecast, 2017 - 2028 (Revenue - US$ Mn)
7.2.1. Lung Cancer
7.2.2. Colorectal Cancer
7.2.3. Breast Cancer
7.2.4. Prostate Cancer
7.2.5. Blood Cancer
7.2.6. Others

Complete Report @ https://statisticalinsights.com/main-report/12-Cancer-Drugs-Market.php

Continue…

About The Statistical Insights

The Statistical Insights is one of the largest collections of market research reports from numerous publishers. We have a team of industry specialists providing unbiased insights on reports to best meet the requirements of our clients. We offer a comprehensive collection of competitive market research reports from a number of global leaders across industry segments.
The research reports by The Statistical Insights, are produced by experienced market researchers. Reports will have in-depth analysis about-

CONTACT US

sales@statisticalinsights.com

Phone:
+ (210) 775-2636 (USA)
+ (91) 853 060 7487

 Website @ https://www.statisticalinsights.com/